Fischer, C.; Turchinovich, A.; Feisst, M.; Riedel, F.; Haßdenteufel, K.; Scharli, P.; Hartkopf, A.D.; Brucker, S.Y.; Michel, L.; Burwinkel, B.;
et al. Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment. Int. J. Mol. Sci. 2022, 23, 9535.
https://doi.org/10.3390/ijms23179535
AMA Style
Fischer C, Turchinovich A, Feisst M, Riedel F, Haßdenteufel K, Scharli P, Hartkopf AD, Brucker SY, Michel L, Burwinkel B,
et al. Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment. International Journal of Molecular Sciences. 2022; 23(17):9535.
https://doi.org/10.3390/ijms23179535
Chicago/Turabian Style
Fischer, Chiara, Andrey Turchinovich, Manuel Feisst, Fabian Riedel, Kathrin Haßdenteufel, Philipp Scharli, Andreas D. Hartkopf, Sara Y. Brucker, Laura Michel, Barbara Burwinkel,
and et al. 2022. "Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment" International Journal of Molecular Sciences 23, no. 17: 9535.
https://doi.org/10.3390/ijms23179535
APA Style
Fischer, C., Turchinovich, A., Feisst, M., Riedel, F., Haßdenteufel, K., Scharli, P., Hartkopf, A. D., Brucker, S. Y., Michel, L., Burwinkel, B., Schneeweiss, A., Wallwiener, M., & Deutsch, T. M.
(2022). Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment. International Journal of Molecular Sciences, 23(17), 9535.
https://doi.org/10.3390/ijms23179535